CytomX Therapeutics (CTMX) Treasury Shares (2021 - 2026)

CytomX Therapeutics has reported Treasury Shares for 6 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 209.01% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 209.01% YoY), and the FY2025 full-year result was $2.9 million, up 57.09% from the prior year.
• Treasury Shares for Q1 2026 stood at $2.7 million, down from $2.9 million in the prior quarter.
• The five-year high for Treasury Shares was $2.9 million in Q4 2025, with the low at $387500.0 in Q2 2022.
• Historically, Treasury Shares has averaged $1.6 million across 5 years, with a median of $1.5 million in 2023.
• Annual changes were most pronounced in 2023 — Treasury Shares surged 284.76% — and 2025, when it tumbled 51.76%.
• CytomX Therapeutics' Treasury Shares stood at $1.2 million in 2022, then climbed by 15.47% to $1.4 million in 2023, then soared by 32.32% to $1.9 million in 2024, then jumped by 57.09% to $2.9 million in 2025, then dropped by 8.72% to $2.7 million in 2026.
• The last three Treasury Shares figures came in at $2.7 million (Q1 2026), $2.9 million (Q4 2025), and $998350.0 (Q3 2025), per Business Quant data.